Anti-Hyperglycemic Agents Market (2025 - 2035)

Anti-Hyperglycemic Agents Market Size and Share Forecast Outlook (2025 to 2035)

The anti-hyperglycemic agents market is valued at USD 50.23 billion in 2025. As per FMI's analysis, the anti-hyperglycemic agents market will grow at a CAGR of 4.7% and reachUSD 80.05 billion by 2035. The anti-hyperglycemic agents market has been steadily growing due to the increasing prevalence of diabetes worldwide and the growing awareness regarding blood glucose monitoring.

In 2024, the industry for anti-hyperglycemic agents saw significant changes, especially with the launch of biosimilars and generics. Glenmark Pharmaceuticals introduced Lirafit, the first biosimilar of Liraglutide, as a more affordable option for the treatment of type 2 diabetes. The launch improved access to sophisticated treatment for patients, particularly in the developing world.

This growth is driven by progress in drug discovery, increased healthcare access, and an aging population prone to type 2 diabetes Anti-hyperglycemic agents include insulin and non-insulin drugs, which are crucial for managing blood glucose levels and preventing diabetes-related complications. Rising trends of combination therapies and the creation of innovative delivery techniques are other growth epiphanies of the sector.

Key Market Insights

Comprehensive Market Analysis of Anti-Hyperglycemic Agents Market

The anti-hyperglycemic agents sector is the increasing rates of diabetes worldwide and growing need for effective and accessible treatment solutions. Disruptive Innovation in drug classes including GLP-1 receptor agonists and biosimilars is transforming the competitive landscape. Pharma companies that focus on new therapies and emerging industry will benefit as the sector grows, while those that are slow to adapt will lag.

Top 3 Strategic Imperatives for Stakeholders

Accelerate Biosimilar and Novel Drug Development

Invest in R&D to develop biosimilars and next-generation anti-hyperglycemic agents such as GLP-1 receptor agonists and SGLT2 inhibitors, which are gaining rapid adoption due to their efficacy and patient compliance benefits.

Expand into High-Growth Emerging Markets

Align go-to-market strategies with expanding diabetic populations in regions like Asia-Pacific and Latin America by tailoring pricing, regulatory, and access models to local segment dynamics.

Strengthen Strategic Partnerships and Distribution Networks

Pursue collaborations with regional healthcare providers, digital health platforms, and distribution partners to enhance reach, streamline supply chains, and capture underserved patient segments more effectively.

Top 3 Risks Stakeholders Must Monitor

1-Year Executive Watchlist

For the Boardroom

To stay ahead, in the company increasing demand for anti-hyperglycemic agents, the client would be best served by ensuring the expedited development of its biosimilars, particularly with regard to GLP-1 receptor agonists and fixed-dose combinations that have shown to enhance adherence. This intelligence clearly demonstrates the pressing need to pivot from a generalized sector strategy to a targeted strategy focusing on high-growth, regulation-ready emerging economies. Now the roadmap has to incorporate your regionalized launch plans, approach to regulatory coordination, and a reworked partnership model with digital health and retail pharmacy ecosystems.

Future Market Insights (FMI) Survey Results: Key Stakeholder Perspectives on the The Anti-Hyperglycemic Agents Market

Key Priorities of Stakeholders

• Effective Glycemic Control: 80% of stakeholders globally identified effective blood glucose management as a "critical" priority, with a focus on medications that offer consistent, long-term control.
• Affordability and Access: 72% emphasized the importance of affordability, especially in emerging sectors, to ensure wide accessibility.
• Patient-Centric Treatments: 68% of healthcare providers highlighted the need for patient-centric drug formulations, such as once-daily medications, to improve adherence.

Regional Variance

• USA: 75% of stakeholders prioritize innovative drugs with quick onset, while only 58% in Japan feel the same.
• Western Europe: 84% of healthcare providers emphasize sustainability, with a preference for drugs with minimal environmental impact, as compared to 52% in the USA.
• Japan/South Korea: 65% focus on compact and highly efficient drugs suited for small to medium-sized populations, while 42% in the USA prioritize drug efficacy for large patient groups.

Adoption of New Technologies

High Variance

• USA: 62% of healthcare providers reported increasing use of continuous glucose monitoring (CGM) technologies alongside anti-hyperglycemic agents, driven by the growing emphasis on personalized treatment plans.
• Western Europe: 50% of stakeholders adopted digital health platforms to track treatment efficacy, especially in the UK (63%).
• Japan: 30% have integrated advanced AI technologies to monitor insulin resistance, but uptake is slower due to cost constraints.
• South Korea: 45% of patients use connected devices that work in tandem with medications to optimize treatment.

Convergent and Divergent Perspectives on ROI

• 70% of USA stakeholders view integration with digital health platforms as "worth the investment" for better management of type 2 diabetes.
• In Japan, only 38% see sufficient ROI from high-tech solutions, given the relatively low technology adoption in smaller clinics.

Formulation and Drug Delivery Preferences

Consensus

• Oral Medications: 67% of global stakeholders prefer oral tablets due to ease of use and patient adherence.

Variance

• Western Europe: 50% of stakeholders opt for fixed-dose combinations (FDCs) that combine multiple medications, as compared to 38% in the USA.
• Japan/South Korea: 41% prefer injectable medications, particularly in South Korea, where diabetes management practices in South Korea are shifting towards more advanced delivery systems.
• USA: 60% continue to prefer long-acting insulins or GLP-1 agonists due to convenience and long-term efficacy.

Price Sensitivity

Shared Challenges

• 85% cited rising drug production costs as a primary concern, with insulin price increases reported globally.

Regional Differences

• USA/Western Europe: 65% would be willing to pay a 10-15% premium for drugs with proven clinical outcomes and convenience features (e.g., once-weekly dosing).
• Japan/South Korea: 70% focus on low-cost generics, with South Korea showing a 40% preference for affordable options due to budget constraints, compared to 22% in the USA.

Pain Points in the Value Chain

Manufacturers

• USA: 55% cited the complexity of regulatory approval processes as a significant challenge, particularly for biologics and combination drugs.
• Western Europe: 48% struggled with navigating differing national reimbursement policies.
• Japan: 60% reported slow regulatory processes, contributing to delayed segment entry.

Distributors

• USA: 70% mentioned long lead times due to bottlenecks in raw material availability.
• Western Europe: 50% faced challenges with pharmaceutical pricing negotiations, impacting profit margins.
• South Korea: 60% encountered difficulties in distributing high-demand drugs due to complex import regulations.

Healthcare Providers

• USA: 43% of doctors cited "insurance reimbursement issues" as a top challenge for offering the best treatment options.
• Western Europe: 38% reported long approval timelines for new drugs from insurance companies.
• Japan: 55% struggled with insufficient drug awareness in rural areas, leading to slow adoption of advanced treatments.

Future Investment Priorities

Alignment

• 78% of global manufacturers plan to invest in research for combination therapies and innovative drug delivery methods (e.g., oral insulin).

Divergence

• USA: 66% are focusing on the development of ultra-long-acting insulins to improve patient adherence.
• Western Europe: 58% prioritize sustainable, low-carbon drug production methods in line with regulatory requirements.
• Japan/South Korea: 52% are investing in smaller, more compact delivery devices to cater to smaller urban and rural populations.

Regulatory Impact

• USA: 68% of stakeholders stated that state-level regulations and insurance company policies significantly impact drug pricing and accessibility.
• Western Europe: 80% view the EU's Health Strategy 2023 to 2027 as a key driver of growth for new diabetes treatments, particularly in terms of regulation for better access.
• Japan/South Korea: 45% felt that regulatory changes have a moderate effect on purchasing decisions, citing a lack of robust enforcement for pricing or quality.

Conclusion: Variance vs. Consensus

• High Consensus: Efficacy, affordability, and patient adherence are critical priorities across all regions, with a strong emphasis on improving treatment outcomes through advanced drug delivery methods.
• Key Variances:
• USA: A strong focus on convenience (e.g., long-acting drugs) vs. Japan/South Korea, where cost-effective solutions remain the priority.
• Western Europe: Leadership in sustainability, with Japan opting for smaller, more compact designs and South Korea prioritizing affordability.
• Strategic Insight: A global strategy must adapt to regional preferences: the USA is moving towards convenience and efficacy, while Asia is more focused on cost-efficiency and compact solutions.

Government Regulations Impact on the Anti-Hyperglycemic Agents Landscape

Country-wise Analysis

United States

The largest share of anti-hyperglycemic agents sector is accounted by the United States, which is driven by the high prevalence of diabetes, the growing geriatric population, and a strong healthcare industry.

In addition, a growing emphasis on personalized medicine, as well as the increasing use of digital health technologies, including continuous glucose monitoring (CGM), will fuel the expansion of the sector. United States is still the major in research and development, where large pharmaceutical companies and biotechnology companies can invest huge amounts of money to find new treatments.

United Kingdom

In theanti-hyperglycemicagents’sector, the United Kingdom is likely to witness a CAGR of 4.5% during 2025 to 2035. As the UK faces an accelerating diabetes epidemic, driven up by increasing obesity rates and an ageing population, the need for novel and better diabetes therapeutics will become increasingly pressing.

The introduction of biosimilars in particular is growing increasingly relevant in the UK, where there is an overwhelming demand for alternatives to biologic therapies. The UK sector has challenges due to pressure on the healthcare budget and limited number of new medications that will be approved for reimbursement to the public.

France

The French sector for anti-hyperglycemic agents is projected to expand at a CAGR of 4.3% during the period 2025 2035. France has a universal healthcare system, which generally provides a wide access to diabetes treatment. Nonetheless, industry access can be difficult for novel anti-hyperglycemic agents because reimbursement policies and pricing controls in France are quite strict.

The approval process is governed by the French Medicines Agency (ANSM), which ensures treatment quality is guaranteed. There is also a trend toward personalized medicine, which will increase the need for newer, more specific anti-hyperglycemic agents.

Germany

Between 2025 and 2035, the anti-hyperglycemic agents sector in Germany is anticipated to grow at a CAGR of 4.8%, based on demand generated by rising patients as well as Germany’s reputation for state-of-the-art medical technology. Germany is among the largest pharmaceutical sectors in Europe, with an established healthcare infrastructure that provides universal access to medicines.

Diabetes is one of the leading chronic diseases in Germany, particularly among older adults, creating a constant need for effective treatments. Quality standards and efficacy are guided by the Federal Institute for Drugs and Medical Devices (BfArM) and are a core part of the German healthcare system where the focus of the healthcare system is cost-effective care.

Italy

The Italy anti-hyperglycemic agents sector is predicted to exhibit a CAGRof 4.1% during the period 2025 to 2035. Most Italians have access to diabetes medications through the Italian public healthcare system in which budgetary constraints on public health expenditure and drug price controls can restrict the supply of new treatments.

Therefore, the use of generic anti-hyperglycemic agents in the country is widespread. There is a growing tidal wave of biosimilars, which are a cheaper alternative for patients. Therapies with improved patient compliance features should start to see wider interest in marketplace.

South Korea

South Korea will hold the CAGR of 5.0% in the anti-hyperglycemicagentssector during 2025 to 2035. The country is experiencing a drastically increasing diabeticdemographic because of the obstreperous changes in lifestyle, urbanization, and an aging society. South Korea provides a well-known vast diabetic treatment through the National Health Insurance Service (NHIS.

The sector is moving towards solutions that are driven by technology, which consist of CGM systems as well as insulin pumps. The approval process is governed by the Korean Food and Drug Administration (KFDA), with high standards for drug efficacy and safety.

Japan

The CAGR for Japan in the anti-hyperglycemicagents sector is expected to be around 4.2% from 2025 to 2035. Japan, which has one of the oldest populations in the world, is experiencing a surge in the prevalence of diabetes and worsening type 2 diabetes.

Diabetes care in Japan has renewed preventive intervention on chronic diseases by implementing large measures through the Japanese government; however, chronic disease remains a prevalence burden. The country has a strong health care system, emphasizing innovation in treatments, but high drug prices and an aging population pose challenges. The Pharmaceuticals and Medical Devices Agency (PMDA) is responsible for the approval of new anti-hyperglycemic agents with a priority on the efficacy and safety.

China

China sector for anti-hyperglycemic agents is expected to grow at a CAGR of 6.0% during the period 2025 to 2035, supported by a progressive rise in the number of patients with diabetes and the progression of middle class.

Fast-aging and increasingly urbanized Chinese population, the need for effective diabetes treatment can only grow. Drug approval is overseen by the National Medical Products Administration (NMPA), and in recent years, there has been a growing regulatory ease towards biosimilars as well as generic drugs, which has also helped bring down costs of diabetes management.

Australia & New Zealand

The anti-hyperglycemic agents sector will grow at a CAGR of 4.6% in Australia and New Zealand from 2025 to 2035. Both countries experience soaring rates of diabetes fueled by obesity and lifestyle changes. The nations have developed healthcare systems with government programs designed to mitigate the impact of chronic conditions such as diabetes.

While in Australia, the PBS (Pharmaceutical Benefits Scheme) has made anti-hyperglycemic agents affordable via subsidization for the majority of the population. The pressures on drug pricing and the government’s emphasis on cost-effective treatments may restrict the availability of some newer therapies.

Segment-wise Analysis

By Drug

Sodium-Glucose Cotransport-2 (SGLT-2) inhibitors are anticipated to be the most profitable segment between 2025 and 2035 with a CAGR of 6.2%, witnessing tremendous growth on the back of a mix of growing adoption, new indications, and patient-beneficial benefits.

This class, represented by medications such as empagliflozin, canagliflozin, and dapagliflozin, has emerged as one of the most sought-after treatment options for the management of type 2 diabetes, and its industry share will keep on increasing throughout the forecast period. The success of SGLT-2 inhibitors is largely due to their dual advantages - not only do they lower blood glucose, but they also offer cardiovascular and renal protection.

By Distribution Channel

Online Pharmacies will be the most profitable segment between 2025 and 2035, with the highest growth spurred on by growing digitalization of healthcare and consumers' growing preference for home delivery and convenience services with a CAGR of 7.5%.

The trend towards e-commerce and digital healthcare solutions has been gaining pace, particularly in the wake of the COVID-19 pandemic, and is also set to persist. Internet pharmacies have tremendous benefits for long-term patients such as those with diabetes, in that they provide convenient access, home delivery, and cost comparison.

Competitive Landscape

Players are becoming competitive in the anti-hyperglycemicagents sector with their pricing, innovative approach, partnerships, and organic and inorganic growth strategies. Pricing is an important factor, leading many companies to strategically price their drugs so as to offer a competitive price for the generic equivalents to parallel products, including Metformin and DPP-4 inhibitors. Top firms are investing heavily behind R&D to bring forward new drugs and combination therapies that can manage wider areas of diabetes, including cardiovascular risk and chronic kidney disease.

Market Share Analysis

• Novo Nordisk (38.6% share)Dominates with GLP-1 agonists Ozempic® and Rybelsus®, capturing 72% of the GLP-industry. Maintains lead through superior HbA1c reduction (1.8-2.0% in trials) and obesity-diabetes combo therapies. Recent FDA approval for oral semaglutide expanded industry reach.Source: Novo Nordisk FY2024 Diabetes Report
• Eli Lilly (31.2% share)Driven by Mounjaro® (tirzepatide) showing 2.4% HbA1c reduction - the highest in class. Investing USD 2.5B in new EU/US manufacturing facilities to meet demand. GIP/GLP-1 dual mechanism sets new efficacy benchmarks.Source: Lilly 2024 Investor Briefing
• Merck & Co. (12.8% share)Januvia® remains top DPP-4 inhibitor despite patent cliffs, with USD 3.8B 2024 sales. Developing oral GLP-1 candidates to challenge injectables. Stronghold in price-sensitive sectors with generic collaborations.Source: Merck Q2 2024 Financials
• AstraZeneca (8.4% share)Farxiga® leads SGLT2 segment with 2024 CKD/HF indication expansions (28% sales growth YoY). Partnering with Indian generics for emerging sector penetration. Investing in dual SGLT2/GLP-1 combos.Source: AZ Therapy Area Report 2024
• Sanofi (5.1% share)Focusing on next-gen Toujeo® (U300 glargine) after Lantus® divestment. Holds #1 EU insulin position but losing USA ground to biologics. Exploring smart insulin pens with CGM integration.Source: Sanofi Diabetes Division 2024 Update

Key Developments

• Lupin's Acquisition of Diabetes Trademarks (December 2024): Lupin Limited acquired three anti-diabetes trademarks-GIBTULIO®, GIBTULIO MET®, and AJADUO®-from BoehringerIngelheim International GmbH. This acquisition aims to strengthen Lupin's diabetes portfolio in India, with the trademark rights expected to transfer by March 2025.

(Source: The Economic Times)

• Lupin's Acquisition of Ondero and Ondero Met Brands (August 2024): Lupin acquired the trademarks for Ondero (linagliptin) and Ondero Met (linagliptin + metformin) from BoehringerIngelheim. Lupin has been marketing these brands since 2015 under a co-marketing agreement with BoehringerIngelheim India. This acquisition enhances Lupin's position in the anti-diabetes segment in India. ​

(ETHealthworld.com)

Key Players

• Novo Nordisk
• Sanofi
• Merck & Co.
• BoehringerIngelheim
• Eli Lilly
• Bristol-Myers Squibb
• Johnson & Johnson
• AstraZeneca
• GlaxoSmithKline
• Lupin Pharmaceuticals
• Amgen
• Bayer

Anti-Hyperglycemic Agents Market Analysis by Key Segments

By Drug:

the industry is segmented into Biguanides, Alpha-glucosidase inhibitors, Dopamine-D2 Receptor Agonist, Sodium-glucose Cotransport-2 (SGLT-2) inhibitor, Dipeptidyl Peptidase-4 (DPP-4) Inhibitors, Sulfonylureas, Meglitinides, and Others

By Distribution Channel:

the industry is segmented into Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies

By Region:

the industry is segmented into North America, Latin America, Europe, East Asia, South Asia, Oceania, The Middle East & Africa